Balyasny Asset Management
VOR icon

Balyasny Asset Management’s Vor Biopharma VOR Stock Holding History

Balyasny Asset Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-631
Closed -$67.9K – 2836
2023
Q1 		$67.9K Buy
+631
New +$69.9K ﹤0.01% 2354

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Balyasny Asset Management's VOR Position: Q2 2023 in Review

Balyasny Asset Management sold out of Vor Biopharma (VOR) in Q2 2023, closing a stake of 631 shares — an estimated $67.9K sold.

Balyasny Asset Management first reported a position in VOR in Q1 2023 and held it in 1 quarter. The position peaked at $67.9K in Q1 2023. 71 funds tracked by Wall St. Rank hold VOR as of Q2 2023.

  • Balyasny Asset Management reported no remaining Vor Biopharma position as of Q2 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 631 Vor Biopharma shares in Q2 2023, an estimated $67.9K.
  • Balyasny Asset Management first reported a position in Vor Biopharma in Q1 2023 and held it in 1 quarter.
  • Balyasny Asset Management's Vor Biopharma position peaked at $67.9K in Q1 2023.
  • 71 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.